Background
Complete removal of necrosis is critical for treating patients with severe acute pancreatitis (SAP) presenting infection of pancreatic necrosis (IPN). Frequently used mini-invasive methods include the surgical step-up approach suitable for necrosis extending laterally, whereas the endoscopic step-up approach is suitable for medial necrosis. This retrospective study evaluated a combined mini-invasive step-up approach for treating extensive IPN.
Methods
Seven patients with SAP and extensive IPN were enrolled. All patients underwent a combined step-up approach comprising four steps: percutaneous catheter drainage (PCD), continuous negative pressure irrigation (CNPI), percutaneous endoscopic necrosectomy (PEN), and transgastric necrosectomy (TN). A lumen-apposing metal stent was used in the TN to shorten the operative time, thereby improving patient tolerance. The details of each step, including timing, frequency, and duration, as well as clinical outcomes of study patients were analyzed.
Results
The median interval from symptom onset to PCD and CNPI was 11 days (range, 6–14) and 18 days (range, 14–26), and the median CNPI duration was 84 days (range, 54–116). The median interval from the onset of symptoms to PEN and TN was 36 days (range, 23–42) and 41 days (range, 34–48), respectively, and the median number of procedures was 2 (range, 1–2) and 3 (range, 2–4). Only a minor case of abdominal bleeding and a pancreatic-cutaneous fistula were reported, both resolved after conservative treatment. The median length of stay in the intensive care unit was 111 days (range, 73–133); all patients survived.
Conclusions
This mini-invasive step-up approach shows promising clinical effects and is relatively safe in critically ill patients with extensive IPN and high-risk surgical intervention. Future clinical studies with larger samples are needed to verify this approach.
Trial registration:
The study protocol was approved by the Medical Ethics Committee of Nanjing Drum Tower Hospital (number:2021-147-01). This study was retrospectively registered in the Clinical Trial Registry (www.clinicaltrials.gov) on August 16, 2022, and the identifier was NCT05508828.